BuzzSparks.org

Concert Pharmaceuticals


Biotechnology company

Founded in April 2006, Concert Pharmaceuticals is a clinical stage biotechnology company dedicated to creating new medicines through a novel scientific approach utilizing the naturally-occurring element deuterium. Concert applies its innovative...

Founded in 2006
Homepage:
Total money raised: $99.5M

Corporate Headquarters

02421 99 Hayden Avenue
Suite 500

Lexington
USA MA

Phone: 781.860.0045

Updated on Aug 28, 2012
Concert Pharmaceuticals at CrunchBase
Roger Tung President and CEO
Steve Bernitz Chief Business Officer
Robert Silverman Vice President and General Counsel
Nancy Stuart COO
Wilfred Jaeger Director
Robert Zelle Vice President, Drug Development
Past

February, 2012

Concert Pharma snags $200M licensing pact with Avanir    fiercebiotech.com

June, 2011

Concert Pharmaceuticals raised $4M in unattributed round from GlaxoSmithKline

Concert Pharmaceuticals lands $4M milestone pay    masshightech.com

April, 2011

has made two new executive appointments

Concert Pharmaceuticals names Roessel, Sabounjian to exec roles    masshightech.com

February, 2011

Concert Pharmaceuticals, Walter Reed partner on seizure teatment    masshightech.com

November, 2009

Concert Pharmaceuticals to land $12M from HIV drug's clinical study

Mass High Tech    masshightech.com

April, 2008

Concert Pharmaceuticals raised $37M in a Series C round from QVT Financial, GSK Venture Fund, Mediphase Venture Partners, Westfield Capital Management, Three Arch Partners, Skyline Ventures, TVM Capital, Brookside Capital, New Leaf Venture Partners, Flagship Ventures, Adage Capital Management, and Greylock Partners

November, 2006

Concert Pharmaceuticals raised $48.5M in a Series B round from Flagship Ventures, Brookside Capital, New Leaf Venture Partners, Three Arch Partners, TVM Capital, Skyline Ventures, Greylock Partners, and QVT Financial

Concert Pharmaceuticals Raises $48.5 Million in Series B Financing    concertpharma.com

July, 2006

Concert Pharmaceuticals raised $10M in a Series A round from Three Arch Partners, TVM Capital, Skyline Ventures, Greylock Partners, and QVT Financial

Concert Pharmaceuticals, Inc.,â„¢ Announces Financing of its Series A Round    concertpharma.com

2006

Concert Pharmaceuticals was founded in 2006